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Background: With increasing human longevity there is increasing prevalence of osteoporosis and of osteoporotic
vertebral fractures. Most vertebral fractures do not require medical therapy for pain, but a minority are associated
with severe pain and disability.
Vertebroplasty has been used increasingly for painful acute osteoporotic fractures. The best available evidence for
vertebroplasty is provided by two placebo controlled trials which showed no significant clinical benefit of vertebroplasty
over placebo. These were not acute fracture trials with the majority of fractures in both trials being well beyond the
acute time frame of 6 weeks. There is evidence from an open label randomized controlled trial of vertebroplasty versus
conservative therapy in acute fractures suggesting clinical efficacy in acute vertebral fractures.
Methods: This is a blinded trial of Vertebroplasty for Acute Painful Osteoporotic fractURes - the VAPOUR trial. Patients
greater than 60 years in age with new severe onset of back pain and osteoporotic vertebral fractures of less than 6 weeks
duration will be enrolled. They will be randomized to receive either vertebroplasty or a placebo procedure. Data regarding
pain, disability, and quality of life will be collected over a 6-month period. The enrolled patients and the outcome
assessors will remain blinded for the duration of the trial.
Discussion: The VAPOUR trial will apply similar methodology to the previous blinded trials but in a patient group with
exclusively acute fractures and the most severe pain.
Trial registration: ClinicalTrials.gov trial identifier: NCT01482793 registered on 28 November 2011.
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With increasing human longevity there is increasing
prevalence of osteoporosis. Vertebral body fractures are
among the most common osteoporotic fractures. Whilst
most cause minimal symptoms, a subset can cause severe
acute fracture pain. Vertebroplasty has become a com-
monly used procedure for the management of painful
osteoporotic vertebral fractures.
There is conflict in the best published evidence for
vertebroplasty. There are two blinded randomized
controlled trials (RCTs) published together in 2009 [1,2]
which provide the highest quality evidence at present and* Correspondence: williamxrayclark@bigpond.com
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unless otherwise stated.show no benefit of vertebroplasty over placebo at any
time point. Both enrolled similar patient groups, with
osteoporotic fractures and back pain for up to 1 year.
The average durations of back pain in these trials
were 16 to 18 weeks in the larger trial [1] and 10 weeks in
the smaller trial [2]. Neither trial found significant clinical
advantage over placebo in the vertebroplasty group at
any time point.
The largest open label RCT of vertebroplasty [3] limited
enrolment to painful fractures less than 6 weeks duration.
This trial compared vertebroplasty to usual care and found
positively for vertebroplasty with enhanced reduction in
pain score and also in the Roland Morris Disability score
in the vertebroplasty group at each time point out to
12 months following the intervention. Similar findings
were obtained in a large open label RCT of kyphoplastyhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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fracture pain less than 3 months duration.
A debate developed regarding the apparent discrepancy
in findings between the blinded and the open label trials.
Proponents of vertebroplasty argued that patient selection
and procedural technique explained the negative findings
in the blinded trials [5,6]. The Vertos II trial [3] was a trial
of vertebroplasty for acute fractures whereas the two
blinded trials [1,2] included predominantly non-acute
fractures where the bone may have already healed.
Patient selection could explain the difference. Technical
considerations, and in particular the small volume of
cement injected, were also questioned in the blinded
trials [7]. Conversely, evidence-based medicine experts
have argued that the design of the blinded trials was
superior and that the apparent efficacy of vertebroplasty
in the Vertos II trial was due to a placebo effect and the
inherent bias in an open label trial [8-10].
A meta-analysis [11] of the two blinded RCTs
attempted to answer the remaining question about the
efficacy of vertebroplasty in the acute setting. The
authors found 57 patients (25 vertebroplasty and 32
controls) from the combined enrolment of both blinded
RCTs [1,2] to have had back pain for less than 6 weeks.
This meta-analysis found no benefit of vertebroplasty over
placebo at one week or one month. Analysis beyond one
month was not presented. This meta-analysis contained
little technical data with no reporting of the vertebral
fracture levels, the inclusion of inpatients or not
(inpatients were completely excluded in the larger trial
and not reported in the smaller trial), and the cement
volume injected (average 2.6 cc for both trials overall, but
no reporting for this sub-group meta-analysis).
There is clearly a requirement for a resolution of the
conflicting clinical evidence for vertebroplasty in the
acute fracture setting. This requires a blinded RCT of
vertebroplasty for acute vertebral fractures (defined as
less than 6 weeks duration) with new onset of severe
back pain (defined as pain score greater than 7/10). We are
conducting such a trial: Vertebroplasty for Acute Painful
Osteoporotic vertebral fractURes (The VAPOUR Trial).
Mechanics of vertebroplasty
The mechanics of vertebroplasty underpin the treatment’s
application and patient selection, and these principles need
be clarified as they affect study design. We hypothesize that
vertebroplasty is only effective when applied in the acute
fracture setting in patients with severe pain. It can then
potentially provide internal fixation and ameliorate the
acute pain generated by fracture fragment motion. To
achieve adequate internal fixation in a collapsing bone, we
believe that the volume of injected cement is important to
outcome and this volume will be measured. We also
hypothesize that fractures in different parts of the spine aresubject to different biomechanical forces which affect
fracture behaviour. These segments may therefore
respond differently to vertebroplasty. We will analyze
the sub-groups of thoracic (T4-T10), thoraco-lumbar
(T11-L2) and lumbar (L3-L5) as categorized in previous
RCTs of spinal augmentation [3,4]. It is our anecdotal
belief that the thoraco-lumbar segment is the region of
the spine that responds best to vertebroplasty in the acute
setting. This is the segment that is exposed to the lar-
gest flexion forces and accounts for the majority of
“osteonecrotic” fracture clefts filled with either fluid
or gas [12-14]. It has been previously demonstrated that
thoracolumbar fractures are predisposed to “dynamic
mobility” [15] which means that the vertebral body
assumes different volumes in the erect and supine (or
prone) positions. Such a fracture should benefit the most
symptomatic relief from internal fracture fixation afforded
by vertebroplasty by reducing fracture fragment motion.
The thoracic vertebrae (T4 to T10) undergo relatively
reduced flexion force due to the bracing of the posterior
elements by the rib cage. The reduced force across the
fracture line in the thoracic segment may imply that
natural healing is improved and that less mechanical
advantage is obtained from vertebroplasty.
Methods/design
Trial design
The trial is a participant and outcome-assessor blinded
randomized controlled trial of vertebroplasty for acute
fractures. Acute fracture will be defined as new severe
onset of back pain (of less than 6 weeks duration)
associated with magnetic resonance imaging (MRI) or
single-photon emission computed tomography (SPECT)-
computed tomography (CT) evidence consistent with a
recent fracture. MRI or SPECT-CT must be obtained
within a week of patient enrolment. The MRI will include
sagittal T1 weighted and fat suppressed T2 weighted
images of the thoracic and lumbar spine. Deformity of the
vertebral body associated with the high signal pattern (T2)
and low signal pattern (T1) of acute fracture within the
vertebral body will define recent fracture. Note that
the precise duration of fracture is defined by careful
questioning of the patient as to the date of onset of
severe pain. The pain location should be consistent
with the recent fracture identified on MRI. When
MRI is contraindicated, then SPECT-CT will be obtained.
Increased radioisotope uptake in the pattern of recent
fracture associated with fracture deformity of the vertebral
body will be accepted as evidence of recent fracture.
The trial is of essentially similar design as the previous
two blinded RCTs [1,2]. It is a multicentre trial involving
four centres in Sydney, Australia that have established
vertebroplasty programs. Data will be collected at baseline,
3 days, 2 weeks, 1 month, 3 months and 6 months post
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blinded for the duration of the trial.
Patient selection
Patients referred for vertebroplasty will be screened for
eligibility according to principle inclusion and exclusion
criteria (Table 1). Those patients who are eligible for
enrolment will be offered entrance into the trial.
Vertebroplasty will not be available outside of the
vertebroplasty trial, so that eligible patients are offered
the choice between conservative care and enrolment in the
trial. Ineligible patients will not be offered vertebroplasty.
The conflicting evidence for the role of vertebroplasty in
the management of acute osteoporotic fractures will be
explained to the patient by the referring physician and the
interventional radiologist. Informed consent to participate
in the trial will be obtained prior to patient enrolment.
Baseline assessment
After the patient has consented to inclusion in the trial,
baseline medical history including general medical history,
history of osteoporosis, previous fractures, previous spinal
interventions and medications is recorded. Baseline
measure of numeric pain scores and visual analogue
pain scores are collected together with Roland Morris
Disability score, QUALLEFFO quality of life, medication
usage and EQ-5D. The baseline assessment is collected
either on the day of the procedure or the day prior to the
procedure, depending upon patient convenience.
Random allocation
The subjects will be randomized to either the control
intervention group or the vertebroplasty group using
the method of minimization. This will be performed
centrally at the National Health and Medical Research
Council (NHMRC) Clinical Trials Centre, University
of Sydney. The call to the NHMRC Clinical Trials Centre
will be made once the patient is in the procedure room
immediately prior to the procedure.
Randomization will be 1:1 to each treatment arm,
and patients will be stratified by the following factors:Table 1 Principle inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
Age >60 Inability to provide informed
consent
Pain from one or two acute
vertebral fractures
Chronic back pain requiring
narcotic analgesia
MRI or SPECT-CT obtained within
previous week
Presence of sciatica
Duration of fracture pain <6 weeks Significant retropulsion into
spinal canal
Pain >7/10 on numeric scale Evidence of spinal malignancy
Patient can speak English Active systemic infection* Age (<75, ≥75 years) * Degree of bone height loss
(<50%, ≥50%) * Fracture due to trauma (Yes, No) * Patient
taking steroids (Yes, No) * Hospital/site.
Procedures
Patient will be laid prone on the procedure table and an
oxygen mask applied. Pulse oximetry monitoring will be
used continuously to monitor arterial oxygen saturation
and pulse rate. Conscious sedation, comprising midazolam
and fentanyl, will be administered intravenously.
Vertebroplasty will be performed according to the
standard practice of the Interventional Radiology investi-
gators in the trial. Local anesthetic will be injected into
the soft tissues of the back and a 4-mm skin incision made
to allow entrance of the vertebroplasty needle. An
11-gauge or 13-gauge vertebroplasty needle will be
introduced into the vertebral body using a transpedicular
approach and fluoroscopic imaging guidance. Either a
unipedicular or bipedicular approach can be employed de-
pending upon operator preference. AVAMAX (CareFusion
Corporation) bone cement will be used for all vertebro-
plasty procedures. The cement is injected into the vertebral
body using the approved kit technique during continuous
fluoroscopic screening. The injection will be terminated
when there is satisfactory distribution of the cement or if
there is any cement leak into an adjacent structure. The
proceduralists have been advised to attempt “maximal fill”
of the vertebral body where possible. Ideally this means a
cement distribution from the superior to the inferior end
plate, from the medial cortex of the pedicle to the medial
cortex of the contralateral pedicle and from the anterior
cortex of the vertebral body to the posterior third of the
vertebral body. Cement injection is always performed in the
lateral screening projection with intermittent fluoroscopic
checking in the anteroposterior (AP) projection. When
these fluoroscopic end points are achieved in the AP
and lateral projections, the injection is ceased. If there
is significant venous, disc or spinal canal cement
extrusion observed, then the injection is terminated.
The vertebroplasty kits used in this trial include an
injecting syringe with clear volumetric markings
which facilitates volume measurement. The volume of
cement injected in each vertebroplasty case will be
recorded accurately.
The control intervention is designed to simulate the
procedural patient experience of a vertebroplasty. After
administration of conscious sedation, local anesthetic
will be injected into the subcutaneous tissues of the
back in the vicinity of the fracture. A 4-mm skin inci-
sion is made and light tapping on the skin will be made to
simulate vertebroplasty needle advance. Conversation
regarding cement mixing and injection will be made
by the operator to suggest a vertebroplasty is being
performed.
Clark et al. Trials  (2015) 16:159 Page 4 of 7Measures
Data will be recorded at baseline, 3 days, 14 days, and 1,
3 and 6 months following procedure. During the baseline
consultation patient questionnaires will be administered
in a face-to-face interview. The 2-week and 6-month
interviews will also be conducted in person by research
staff during patient visits. The other interviews (day 3,
month 1 and month 3) will be conducted by the same
research staff by telephone. An exception to this will
be inpatients that remain in hospital at day 3 who
may be interviewed at bedside. The schedule of these
data points is presented in Table 2.
The numeric rated scale (NRS) of pain will be used at
all data collection points. Patients will be asked to answer
with a number between 0 to 10 to estimate their pain
intensity. This is the primary outcome measure. To
standardize results, the primary pain question is the
same as that used in the INVEST Trial [16], the larger of
the published blinded trials of vertebroplasty. This primary
pain score will record pain over the previous 24 hours.
Separate numeric pain scores at rest and during standing
or moving will also be obtained.
Visual analogue scale (VAS) of pain will be recorded at
the three clinic visits (baseline, 2 weeks and 6 months
post procedure). This score will be obtained by asking
the patient to make a mark on a line which is 10 cm in
length in answer to the primary pain question. The line
is marked “no pain” at the left extreme and “worst
possible pain” at the right extreme. There are no other
divisions or marks on the line. This VAS measure is
recorded for overall pain over previous 24 hours as
well as separate measures for pain at rest and during
walking or activity. This VAS pain score will supplementTable 2 Schedule for data collection
Evaluations Visit baselin
Procedure/operative information X
Pain NRS Questionnaire X
Pain VAS Questionnaire X
Physicians VAS Questionnaire X
Roland-Morris Low Back Pain and Disability Questionnaire X
Osteoporosis Quality of Life Questionnaire (QUALEFFO) X
EQ-5D Questionnaire X
Change in pain
Perception of treatment assignment
Pain medication X
Timed up and go test X
Adverse events
Resource use/health care utilization information
Erect spinal X-ray Xthe NRS pain score at these three time points including the
primary end point (NRS pain at 2 weeks post procedure).
The subjective nature of patient reported pain is
problematic and thus the dual pain measurements.
The researcher will also record their own estimate of
patient pain at the clinic visits.
The Roland-Morris Low Back Pain and Disability
Questionnaire (RDQ) is a 24-item back pain specific
functional status questionnaire [17]. It consists of 24
yes/no items, which represent common dysfunctions in
daily activities experienced by patients with back pain.
Scores range from 0 to 24, with higher numbers indicating
worse physical functioning. This score will be collected at
all data collection time points.
The Quality of Life Questionnaire of the European
Foundation for Osteoporosis (QUALEFFO) comprises
41 quality of life questions and includes five domains:
(A) pain; (B, C, D) physical function; (E) social func-
tion; (F) general health perception and (G) mental
function [18]. The physical function domain is sepa-
rated into three sub-domains: activities of daily living
(B), jobs around the house (C) and mobility (D), so
there are effectively seven categories. Each of these
seven categories will be individually scored in addition to
an overall score. This questionnaire is quite time con-
suming and lengthy for the elderly, frail patients in
this trial. For this reason it will be administered at
baseline, 2 weeks, one month and 6 months but not
at 3 days and 3 months.
The European Quality of Life - 5 Dimensions (EQ-5D)
is a health questionnaire [19]. This scale is a standardized
instrument for use as a measure of health outcome. Scores
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be recorded at all data collection time points.
Analgesic consumption will be recorded at each time
point. This will include the daily dose of each analgesic.
Each medication will be classified as “strong opioid”,
“mild opioid” or “non-narcotic analgesic” according to
opioid comparative information published in the Australian
Medicines Handbook [20]. The opioids classified as “strong”
include oxycodone, morphine, fentanyl, pethidine,
hydromorphone, buprenorphine and tramadol. The opioids
classified as “mild” include medications containing codeine
or dextropropoxyphene. The non-opioid medications
include paracetamol and non-steroidal anti-inflammatory
drugs (NSAIDs). The patient will be given a score of 0, 1 or
2 in each of these three analgesic medication categories
depending on the number of concurrent different
medications being taken within each category. If the
patient is taking two different “strong” opioid preparations,
for example one prolonged release and another for
breakthrough pain, then the score in the strong narcotic
category will be 2. If the patient is using one strong opioid
medication the score in this category will be 1. If the
patient is taking no “mild” narcotics the score in that
category is zero. If the patient is taking either paracetamol
or an NSAID, then the score in that category will be 1 and
if taking both it will be 2. The scores obtained in each of
these three categories will be compared between the
control and vertebroplasty groups. It is our hypothesis
that the “strong opioid” scores in the vertebroplasty
group will be lower than those of the control group.
In addition the daily opiate dose will be converted into
a morphine dose equivalent using the Opioid Dose
Equivalence, Calculation of oral Morphine Equivalent
Daily Dose oMEDD) [21], published by the Faculty of
Pain Medicine which is a faculty of the Australian
and New Zealand College of Anaesthetists. The morphine
equivalent daily dose at each data point will be compared
between placebo and vertebroplasty groups.
Questions regarding perceived pain change after
procedure, blinding and perception of treatment assign-
ment will be administered at 3 days and 2 weeks. A timed
get up and go test [22], which is a measure of function in
older people, will be performed during clinic visits at
baseline, 2 weeks and 6 months. Questions regarding
duration of hospitalization, resource use and health
care utilization will be collected at 6 months.
Sample size
The primary outcome is the proportion of patients
achieving a 14 day pain score of less than 4 out of 10
(from a baseline score greater than or equal to 7 out of 10).
A sample size of 60 patients per arm will have >80% power
and 95% confidence to detect a difference in this
primary outcome from 35% in the control arm to 65% inthe active arm, allowing for a modest loss to follow-up.
Recruitment is expected to start November 2011 and take
approximately 3 years.
Analysis
Effectiveness analyses will be by the intention-to-treat
principle, whereby patients are analysed according to the
study arm to which they were randomized regardless of
the treatment actually received, and toxicity analyses will
be according to treatment received. Proportions will
be compared using a two-sided chi-squared or exact
(conditional binomial) test. Changes in quality of life
measures (pain and functional disability scores) will
be analysed using t-tests to enable comparisons with
published studies, and non-parametric tests or regression
modelling techniques depending on the distribution of the
data. All comparisons will be two-sided with a significance
level of 5% considered as being statistically significant.
Measures of effect will be presented as either risk differ-
ences, odds ratios or mean differences together with the
respective 95% confidence intervals.
The primary end point is the proportion of patients
whose NRS pain score reduces from 7/10 (or more) to 4/10
(or less) at 14 days. The study sample size is sufficient to
detect an absolute difference of 30% in favour of the
vertebroplasty arm. Sub-group analysis will also be
performed on three different regions of the spine:
thoracic (T4 to T10), thoraco-lumbar (T11 to L2) and
lumbar (L3-L5). Those patients with two acute fractures
involving more than one of these regions will be excluded
from this sub-group analysis. We hypothesize that the
vertebroplasty efficacy will be maximal in the thoracolum-
bar group. We expect the benefit will be greater in
thoraco-lumbar fractures than in thoracic and lumbar
fractures. We hypothesize that the primary end point
(pain score <4/10 at 2 weeks) will be achieved in more than
30% additional patients (than control) in the thoraco-
lumbar fractures and in less than 30% additional patients
(than control) in the thoracic group and the lumbar group.
Note that the trial is not specifically powered for this
sub-group analysis, and the statistical conclusions that
can be drawn from the sub-group analysis will be
limited by the number of patients in each sub-group.
Adverse events
Adverse events will be recorded during the 6 months
post procedure. An adverse event is defined as any
undesirable experience associated with the use of a
medical product in a patient. The event is serious and
should be reported within 24 hours when the patient out-
come is: death, life-threatening, disability or permanent
damage, or the event may jeopardize the patient and may
require medical or surgical intervention (treatment) to
prevent one of the other outcomes.
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physicians will review adverse events during the trial. As
each serious adverse event (SAE) is reported, one of
these physicians will review the details of the SAE within
24 hours. This physician will determine causation
(was the SAE deemed related to the procedure or
not) and, if related to the procedure, was the event
within the adverse events provided in the information
and consent.
The safety review committee will review all SAEs
every 6 months to determine if each SAE was deemed
to have been caused by the procedure or whether the
SAE occurred (or could have occurred) as a result of
comorbidities and factors other than the procedure.
Radiologic measures
Erect radiographs of the thoracic and lumbar spine will
be obtained at baseline and at 6 months in a standardized
fashion to allow comparison of vertebral body heights.
The heights of the fractured vertebral body in the lateral
projection will be measured at the posterior margin,
mid-point and anterior margin of the vertebral body.
It is our hypothesis that vertebroplasty will prevent
loss of vertebral body height in comparison to placebo.
The X-rays will also assess for incident fractures in the
two groups. Radiologic measures will be assessed by two
radiologists by consensus. As it is obvious from the
6 month radiograph whether vertebroplasty has been
administered, these measurements are not blinded.
Ethics
Ethics approval has been received from the Human
Research Ethics Committees of Bellberry Limited
[2011-08-414] and also through the National Ethics
Application Form by Northern Sydney Local Health
District Human Research Ethics Committee [HREC/
11/HAWKE/228]. Local approval was obtained from
South Eastern Sydney local health district governance
for St George Public Hospital [SSA/12/STG/30] and for
Sutherland Hospital [SSA/12/STG/60]. Local approval
was obtained for Liverpool Hospital from South Western
Sydney local health district governance [SSA/12/LPOOL/
45-12/027]. Local approval was obtained for Royal North
Shore Hospital from North Sydney local health district
governance [1301–009 M].
Discussion
Although the majority of osteoporotic fractures cause
minimal morbidity, there is a sub-group of patients that
experience severe pain or immobility. This can be a
turning point in the life of an elderly patient and can be
the difference between independence and institutionalized
care. This patient group may develop complications from
conservative therapy. Such complications could includenarcotic-induced delirium, narcotic-induced constipation,
loss of confidence in mobilizing after prolonged bed rest
and swelling in the lower legs due to prolonged sitting with
the legs not elevated. The principle of acute intervention is
to break this downward spiral and allow early mobilization,
earlier rehabilitation and recovery of independence.
There are several difficulties in conducting a randomized
controlled procedural trial in an elderly population with
acute pain. The primary end point of this trial is the
numeric rated pain score at 2 weeks. Patient-rated pain
score is subjective and can be affected by other factors,
particularly the use of narcotic analgesics. For this reason,
the trial includes two office visits (at 2 weeks and 6 months,
respectively). These visits allow for the collection of a
properly performed visual analogue pain score to supple-
ment and compare with the numeric pain score. The office
visits do make the trial more difficult to conduct as elderly
patients with osteoporotic fractures often have difficulty
arranging transportation and require family members,
often at their inconvenience, to accompany them.
The Roland Morris Disability score will provide
important data as it comprises 24 yes/no questions
relating to low back pain and disability. This measure is
regarded by the authors as of equal importance to the pain
measures. The disability caused by painful spinal fractures
is of just as much clinical importance as the pain itself
and the 24 yes/no questions are perhaps less subjective
than the simple nomination of a pain score. Analgesic use
and duration of hospitalization will also provide objective
although indirect measures related to pain and disability.
The inability to provide informed consent may preclude
a significant number of otherwise eligible patients from
the trial. Elderly patients hospitalized with acute fracture
pain are usually treated with narcotic analgesics which can
induce delirium and lack of clarity in short-term memory.
Patients with chronic back pain are also to be excluded.
These patients may derive a clinical benefit from vertebro-
plasty, but this would less likely translate to a statistically
significant change in pain score if the baseline pain score
is chronically elevated.
Although the trial sites had existing vertebroplasty
programs, we decided at all trial sites to stop offering
vertebroplasty outside of the trial. As the best available
evidence does not support routine use of vertebroplasty,
this was an ethical decision. Patients referred for vertebro-
plasty now have the choice between enrolment in the trial
or conservative therapy. The only means of obtaining a
vertebroplasty is via enrolment in the trial. This facilitates
enrolment into the trial and links the trial directly to real
clinical practice.
There is no crossover in this trial. The larger of the
published blinded RCTs [1] allowed crossover of patients
at one month resulting in 27 of the 61 patients in the
control arm crossing over to the vertebroplasty arm.
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methodology to the previous blinded RCTs but in a
different patient group. This will provide much needed
evidence regarding the clinical efficacy of vertebroplasty
for painful vertebral fractures that are less than 6 weeks in
duration.
Trial status
At the time of writing (5 September 2014) 112 patients
had been enrolled into the trial. At current rates of
enrolment we would anticipate concluding enrolment
in December 2014.
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